Leadership & Pay ·
Candel Therapeutics appoints Martine Zimmermann to its Board of Directors as it prepares for a planned Biologics License Application submission in late 2026
CADLCandel Therapeutics, Inc.
Candel Therapeutics increased its Board of Directors from ten to eleven members and appointed Martine Zimmermann, Pharm.D., as an independent director effective September 8, 2026. Dr. Zimmermann joins the Class III slate with a term expiring at the 2027 Annual Meeting. Her compensation includes a $40,000 annual retainer paid quarterly and an option to purchase 64,000 shares vesting monthly over three years. The appointment adds regulatory and quality expertise as the company prepares for a planned Biologics License Application submission in late 2026. Candel Therapeutics is a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer treatment.